Elevance Health (NYSE:ELV) FY Conference Summary Company Overview - **Company**: Elevance Health - **Date of Conference**: March 10, 2026 Key Points CMS Sanctions and Risk Adjustment Practices - **CMS Concerns**: The Centers for Medicare & Medicaid Services (CMS) raised concerns regarding historical risk adjustment data submission practices for services prior to April 2023, indicating a broader policy and payments dispute rather than just a data submission issue [3][4] - **Actions Taken**: Elevance Health has engaged with CMS in good faith, proactively disclosing potentially unverified diagnosis codes and seeking guidance on handling prior year corrections [4][5] - **Current Practices**: The company asserts that its current risk adjustment practices are compliant with CMS regulations and that the issues raised pertain only to historical practices [11][14] - **Financial Impact**: Elevance expects the resolution of this matter will not alter its capital deployment priorities for 2026, maintaining an outlook of at least $5.5 billion in operating cash flow [8][9] Medicare Advantage Business - **2026 Guidance**: The adjusted earnings guidance for 2026 is reaffirmed at a minimum of $25.50 per share, with a benefit expense ratio of approximately 90.2% [16] - **Enrollment Cycle**: A significant portion of the 2026 enrollment cycle is already completed, which helps mitigate in-year financial implications from potential sanctions [10] - **Margin Improvement**: The company anticipates a margin improvement to at least 2% for Medicare Advantage in 2026 [10] Medicaid Trends - **Cost Trends**: Medicaid cost trends have moderated from low double-digit percentages in 2025 to mid-single digits in 2026, driven by changes in acuity and utilization patterns [22][23] - **Operational Initiatives**: Elevance is focusing on tighter medical and pharmacy cost management, expanded behavioral health interventions, and stronger payment integrity to manage costs effectively [24][25] ACA Membership and Effectuation - **Membership Growth**: ACA membership increased by approximately 10% sequentially, with expectations of year-end enrollment at 900,000, down 30% year-over-year [26][30] - **Effectuation Rates**: Effectuation rates for new sales and active renewals are tracking in line with historical patterns, indicating stability in membership activation [26][27] Strategic Direction and Leadership Transition - **Leadership Changes**: The departure of Peter D. Haytaian does not signal a change in strategy for Carelon, which remains integral to Elevance's enterprise strategy [18][19] - **Focus Areas**: The company is prioritizing revenue growth, margin discipline, and enhancing leadership across Carelon's core businesses [19][20] Investment and Technology Initiatives - **Incremental Investments**: Elevance is investing in digital and AI capabilities, scaling Carelon's services, and quality initiatives, with a focus on integrating these technologies across operations [31][32] - **Expected Outcomes**: The company aims for tangible outcomes such as cost reduction, improved cycle times, and productivity gains through these investments [33] Conclusion - **Overall Outlook**: Elevance Health views the CMS sanctions as a historical policy dispute rather than a structural issue affecting its Medicare Advantage business, maintaining confidence in its operational and financial strategies moving forward [15][14]

Core Insights - UnitedHealth Group raised its annual profit forecast and aims for growth in 2026 and beyond, indicating positive momentum under new CEO Stephen Hemsley [1][3] - The company plans to provide a detailed 2026 forecast in January, with expectations for durable and accelerating growth [1] - Despite optimism, UnitedHealth shares remained flat on the announcement day [1] Financial Performance - UnitedHealth now projects 2025 adjusted profit of at least $16.25 per share, an increase from the previous forecast of $16.00, surpassing analysts' expectations of $16.20 [5] - Analysts anticipate a 2026 profit of $17.59 per share [6] Operational Challenges - Recovery in the Medicaid business is expected to be challenging due to a mismatch between payment rates and medical service costs, likely extending into the next year [2] - Behavioral health, specialty drugs, and home-health services have contributed to higher costs in Medicaid plans during the third quarter [4] Management Strategy - CEO Hemsley is focused on regaining investor and consumer trust following a difficult period for the company, which included various challenges [3] - The new Chief Financial Officer Wayne Devedyt indicated plans to reduce clinical service locations through Optum Health to improve profitability [6] - Shifting to plans with a narrower network of doctors is expected to help recover profit margins for the Optum Health unit [7]

Core Insights - Molina Healthcare, Inc. (MOH) is scheduled to report its second-quarter 2025 results on July 23, 2025, with earnings estimated at $5.56 per share and revenues at $10.84 billion [1][2] Financial Performance - The second-quarter earnings estimate has seen three downward revisions recently, indicating a year-over-year decrease of 5.1% in earnings, while revenues are expected to grow by 9.7% year-over-year [2] - For the full year 2025, the revenue estimate stands at $44.06 billion, reflecting an 8.4% increase year-over-year, but the earnings per share estimate is $22.58, showing a slight decline of 0.3% [5] - Molina Healthcare has beaten consensus estimates in three of the last four quarters, with an average surprise of negative 1.6% [5] Membership and Premiums - The Zacks Consensus Estimate for premiums indicates a growth of 10.1% year-over-year in Q2, with Medicaid premiums expected to grow by 4.1% [7] - Medicaid membership is projected to decrease by 1.2% year-over-year, while Medicare membership is expected to grow by 4.2% [9] - Marketplace membership is anticipated to surge by 63% compared to the previous year [9] Cost and Income Trends - The medical care ratio (MCR) for the Marketplace is expected to rise to 77.49%, up from 71.60% a year ago, while the total MCR is projected at 88.86%, slightly up from 88.60% [9] - Rising costs and lower investment income are contributing to uncertainty regarding an earnings beat, with investment income expected to decline by 12.1% year-over-year [10] - Total operating expenses are predicted to increase by more than 8% from the previous year due to higher medical care costs and general administrative expenses [10] Market Position - The company currently holds a Zacks Rank of 5 (Strong Sell) and an Earnings ESP of -1.09%, indicating a lower likelihood of an earnings beat this quarter [6]

Core Insights - Humana Inc. (HUM) is well-positioned for growth due to improved premium revenues, an aging U.S. population, acquisitions, and strong cash generation abilities [1] - The company has a strong outlook for 2025, with anticipated revenue growth and earnings per share [3][4] Revenue Growth - Humana's premium revenues increased by 10.7% year over year in 2024, driven by a solid customer base in its Medicaid and Medicare operations [5] - The company expects revenues for 2025 to be between $126 billion and $128 billion, reflecting a 7.8% improvement from 2024 [3] Earnings Performance - Humana has consistently outperformed earnings estimates, with an average surprise of 15.35% over the last four quarters [2] Strategic Acquisitions - The company has pursued strategic acquisitions to enhance its capabilities and expand its footprint, including Family Physicians Group, Curo, Enclara, iCare, and Inclusa [7] - The acquisition of Enclara improved hospice pharmacy services, while the iCare deal expanded its Medicare presence in Wisconsin [7] Financial Position - As of December 31, 2024, Humana held cash and investment securities totaling $20.4 billion, significantly exceeding its long-term debt of $11.1 billion [8] - The company anticipates GAAP cash flow from operations to be between $2.4 billion and $2.9 billion for 2025, supporting its capital deployment strategy [8] Market Demand - The growing elderly population in the U.S. is expected to sustain demand for Humana's Medicare plans, supported by its CenterWell brand introduced in 2022 [6]